Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $26,088 | 16 | 49.4% |
| Honoraria | $17,318 | 4 | 32.8% |
| Unspecified | $5,704 | 1 | 10.8% |
| Travel and Lodging | $2,944 | 15 | 5.6% |
| Food and Beverage | $738.91 | 9 | 1.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aadi Bioscience, Inc. | $17,759 | 8 | $0 (2024) |
| GlaxoSmithKline, LLC. | $16,753 | 11 | $0 (2022) |
| Eli Lilly and Company | $7,529 | 6 | $0 (2021) |
| Lilly USA, LLC | $5,698 | 7 | $0 (2017) |
| TESARO, Inc. | $4,704 | 11 | $0 (2019) |
| COMSORT, Inc | $350.00 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,195 | 1 | Aadi Bioscience, Inc. ($6,195) |
| 2023 | $8,997 | 5 | Aadi Bioscience, Inc. ($8,997) |
| 2022 | $2,583 | 3 | Aadi Bioscience, Inc. ($2,567) |
| 2021 | $14,525 | 9 | GlaxoSmithKline, LLC. ($13,475) |
| 2020 | $3,263 | 2 | GlaxoSmithKline, LLC. ($3,263) |
| 2019 | $4,454 | 10 | TESARO, Inc. ($4,454) |
| 2018 | $6,879 | 7 | Eli Lilly and Company ($6,479) |
| 2017 | $5,898 | 8 | Lilly USA, LLC ($5,698) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2024 | Aadi Bioscience, Inc. | — | Honoraria | Cash or cash equivalent | $6,195.00 | General |
| 06/02/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Honoraria | Cash or cash equivalent | $5,280.00 | General |
| Category: Cancer | ||||||
| 06/02/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $134.56 | General |
| Category: Cancer | ||||||
| 02/07/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Honoraria | Cash or cash equivalent | $3,382.50 | General |
| Category: Cancer | ||||||
| 02/07/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Travel and Lodging | Cash or cash equivalent | $185.32 | General |
| Category: Cancer | ||||||
| 02/07/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Cancer | ||||||
| 10/25/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Honoraria | Cash or cash equivalent | $2,460.00 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 10/25/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $106.70 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 02/10/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $3,262.50 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 08/10/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: ONCOLOGY | ||||||
| 05/25/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 05/04/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: ONCOLOGY | ||||||
| 05/04/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| 01/19/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $1,812.50 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,450.00 | General |
| 12/06/2019 | TESARO, Inc. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | TESARO, Inc. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $285.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | TESARO, Inc. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | TESARO, Inc. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $57.30 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $39.28 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 88 | 458 | $258,110 | $39,901 |
| 2022 | 4 | 103 | 361 | $201,065 | $32,174 |
| 2021 | 1 | 70 | 360 | $196,200 | $31,373 |
| 2020 | 2 | 79 | 431 | $222,995 | $31,166 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 441 | $240,345 | $37,126 | 15.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $17,765 | $2,774 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 307 | $167,315 | $26,570 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $15,675 | $2,498 | 15.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 23 | $12,075 | $2,125 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 16 | $6,000 | $981.84 | 16.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 360 | $196,200 | $31,373 | 16.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 67 | 386 | $200,720 | $26,896 | 13.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 45 | $22,275 | $4,270 | 19.2% |
About Dr. Martee Hensley, MD
Dr. Martee Hensley, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801999032.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martee Hensley, MD has received a total of $52,793 in payments from pharmaceutical and medical device companies, with $6,195 received in 2024. These payments were reported across 45 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($26,088).
As a Medicare-enrolled provider, Hensley has provided services to 340 Medicare beneficiaries, totaling 1,610 services with total Medicare billing of $134,613. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 09/06/2006
- Last Updated 04/06/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1801999032
Products in Payments
- ZEJULA (Drug) $16,795
- Fyarro (Drug) $8,997
- FYARRO (Drug) $2,567
- KEYTRUDA (Biological) $350.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555